Nomura Adjusts Sinopharm's Price Target to HK$30.33 From HK$32.39, Keeps at Buy
Morgan Stanley Downgrades JD Health International to Underweight From Equal-weight; Price Target Is HK$20.40
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
Nomura Adjusts Sinopharm Group's Price Target to HK$32.39 Form HK$33.31, Keeps at Buy
Nomura Adjusts JD Health International's Price Target to HK$44 From HK$60, Keeps at Buy
Nomura Adjusts JD Health's Price Target to HK$60 From HK$75, Keeps at Buy
Nomura Adjusts JD Health's Price Target to HK$75 From HK$87, Keeps at Buy
Alibaba Health Information Technology Ltd. Raised to Outperform From Hold by Daiwa Capital Markets
UBS Adjusts Sinopharm Group's Price Target to HK$26 From HK$28, Keeps at Buy
UBS Adjusts Alibaba Health Information Technology's Price Target to HK$4.3 From HK$7.8, Keeps at Neutral